Therapeutic potential of potassium channel modulators for CNS disorders

被引：6

作者：

Clark, AG ^{[1
]}

Booth, SE ^{[1
]}

Morrow, JA ^{[1
]}

机构：

[1] Organon Res Labs Ltd, Newhouse ML1 5SH, Lanark, Scotland

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2003年 / 13卷 / 01期

关键词：

BKCa channel; channelopathy; cognition; depression; epilepsy; K+ channel; K-ATP channel; KCNQ channel; Kv1.1; channel; neuroprotection; pain; SKCa channel; stroke;

D O I：

10.1517/13543776.13.1.23

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Potassium (K+) channels play a pivotal role in the CNS, controlling cell excitability thereby raising their therapeutic application. In realisation of the utility of K+ channels, many pharmaceutical companies have developed a plethora of antagonists and openers for a range of disorders, including stroke, epilepsy, pain and cognition. The most promising targets, including BKCa, SKCa and KCNQ channels, will be reviewed in this article. The focus will be upon the most recent K+ channel modulator patents for CNS disorders and future developments of drugs for the treatment of CNS disorders.

引用

页码：23 / 32

页数：10

共 62 条

[31]

ICAGEN, 2001, Patent No. 0110381

[32] Kaliotoxin, a Kv1.1 and Kv1.3 channel blocker, improves associative learning in rats [J].

Kourrich, S ;

Mourre, C ;

Soumireu-Mourat, B .

BEHAVIOURAL BRAIN RESEARCH, 2001, 120 (01) :35-46

[33]

LY J, 1983, COLD SPRING HARB SYM, V48, P233

[34] Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine [J].

Main, MJ ;

Cryan, JE ;

Dupere, JRB ;

Cox, B ;

Clare, JJ ;

Burbidge, SA .

MOLECULAR PHARMACOLOGY, 2000, 58 (02) :253-262

[35] Control of M-current [J].

Marrion, NV .

ANNUAL REVIEW OF PHYSIOLOGY, 1997, 59 :483-504

[36] Reversible antisense inhibition of Shaker-like Kv1.1 potassium channel expression impairs associative memory in mouse and rat [J].

Meiri, N ;

Ghelardini, C ;

Tesco, G ;

Galeotti, N ;

Dahl, D ;

Tomsic, D ;

Cavallaro, S ;

Quattrone, A ;

Capaccioli, S ;

Bartolini, A ;

Alkon, DL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (09) :4430-4434

[37]

NAGAKI N, 1996, NEURON, V16, P1011

[38]

NEUROSEARCH AS, 2002, Patent No. 0230868

[39]

Ocana M, 1996, J PHARMACOL EXP THER, V276, P1136

[40] SINGLE-DOSE PHARMACOKINETICS, SAFETY, AND TOLERANCE OF LINOPIRDINE (DUP-996) IN HEALTHY-YOUNG ADULTS AND ELDERLY VOLUNTEERS [J].

PIENIASZEK, HJ ;

FISKE, WD ;

SAXTON, TD ;

KIM, YS ;

GARNER, DM ;

XILINAS, M ;

MARTZ, R .

JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (01) :22-30

← 1 2 3 4 5 6 7 →